Hercules Capital

HTGC

Market cap $3B

Maintaining adequate diversification is extremely important. However, unless you have simplifying anchors for a portfolio, it can be very easy to lose proper diversification. I share a portfolio strategy - along with specific picks - that can deliver a diversification, low-stress portfolio that generates very attractive income and dividend growth.

MPLX and Hercules Capital offer high yields near 10% with strong coverage and robust business models, making them compelling income picks. MPLX yields 7.5% with double-digit distribution growth expected through 2027, supported by a 1.3x coverage ratio and expansion in the Permian Basin/Gulf Coast. HTGC delivers an 11.8% yield (including special dividend), maintains near-zero non-accruals, and trades at a 30%+ premium to NAV, reflecting portfolio quality.

Hercules Capital (HTGC) reached $15.69 at the closing of the latest trading day, reflecting a -1.26% change compared to its last close.

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.

In the closing of the recent trading day, Hercules Capital (HTGC) stood at $15.58, denoting a +2.23% move from the preceding trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Hercules Capital stands out among BDCs for its resilient, venture-focused portfolio and minimal AI disruption risk. HTGC maintains strong credit quality, with only 0.1% of its portfolio on non-accrual and a 12% yield, supporting a Strong Buy rating. Portfolio composition is 44% healthcare/life sciences and 35% application software, with high barriers to entry and AI beneficiaries.

Hercules Capital is trading at a 30% premium to NAV, down from 72% in 2024, reflecting compressed sentiment around technology-focused BDCs. HTGC is paying out a 12.1% dividend yield, with a $0.40 base and a $0.07 supplemental quarterly dividend. The base dividend was 120% covered by first-quarter net investment income. Portfolio credit quality remains robust, with nonaccruals at fair value at just 0.1% of the total investment portfolio as of the end of the first quarter.

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets.

Hercules Capital (HTGC) closed the most recent trading day at $15.65, moving +1.03% from the previous trading session.